Owing to significantly prolonged survival,targeted therapy has become standardized recommendation for advanced non-small cell lung cancer patients with mutated driver genes.However,the genetic status of lung cancer pa...Owing to significantly prolonged survival,targeted therapy has become standardized recommendation for advanced non-small cell lung cancer patients with mutated driver genes.However,the genetic status of lung cancer patients is dynamic.By dynamically monitoring the evolution of genes status,differential genes and concomitant genes related to progressive disease could be confirmed early,so as to achieve a more accurate and comprehensive insight of the whole process management of targeted therapy for lung cancer patients.Under the guidance of accurate genetic testing results,it is helpful to provide patients with more effective,long-term,and stable individualized targeted therapy.展开更多
循环肿瘤DNA (Circulating tumor DNA, ctDNA)半衰期很短,可实时和精确地对疾病进行动态监测,作为一种新的诊断生物标志物,其在临床诊断上有广泛的应用前景。结直肠癌(Colorectal cancer, CRC)发病率高,多数CRC在确诊时进入局部进展期,...循环肿瘤DNA (Circulating tumor DNA, ctDNA)半衰期很短,可实时和精确地对疾病进行动态监测,作为一种新的诊断生物标志物,其在临床诊断上有广泛的应用前景。结直肠癌(Colorectal cancer, CRC)发病率高,多数CRC在确诊时进入局部进展期,寻求针对CRC的早期发现、早期诊断的标志物尤为必要。ctDNA在CRC的诊断中已有一定的应用,本文就ctDNA在CRC诊断中的应用进展作一综述。Circulating tumor DNA (ctDNA) has a short half-life and can be used for real-time and accurate dynamic monitoring of disease. As a new diagnostic biomarker, ctDNA has a wide range of clinical applications. Colorectal cancer (CRC) has a high incidence, and most CRC enter the local advanced stage when diagnosed, so it is particularly necessary to seek markers for the early detection and diagnosis of CRC. ctDNA has been used in the diagnosis of CRC. This article reviews the progress of ctDNA in the diagnosis of CRC.展开更多
基金National Natural Science Foundation of China(No.81873396)Capital Health Development Research Project(No.2018-2-4065)Project of China-Japan Friendship Hospital(No.2018-HX-26)。
文摘Owing to significantly prolonged survival,targeted therapy has become standardized recommendation for advanced non-small cell lung cancer patients with mutated driver genes.However,the genetic status of lung cancer patients is dynamic.By dynamically monitoring the evolution of genes status,differential genes and concomitant genes related to progressive disease could be confirmed early,so as to achieve a more accurate and comprehensive insight of the whole process management of targeted therapy for lung cancer patients.Under the guidance of accurate genetic testing results,it is helpful to provide patients with more effective,long-term,and stable individualized targeted therapy.
文摘循环肿瘤DNA (Circulating tumor DNA, ctDNA)半衰期很短,可实时和精确地对疾病进行动态监测,作为一种新的诊断生物标志物,其在临床诊断上有广泛的应用前景。结直肠癌(Colorectal cancer, CRC)发病率高,多数CRC在确诊时进入局部进展期,寻求针对CRC的早期发现、早期诊断的标志物尤为必要。ctDNA在CRC的诊断中已有一定的应用,本文就ctDNA在CRC诊断中的应用进展作一综述。Circulating tumor DNA (ctDNA) has a short half-life and can be used for real-time and accurate dynamic monitoring of disease. As a new diagnostic biomarker, ctDNA has a wide range of clinical applications. Colorectal cancer (CRC) has a high incidence, and most CRC enter the local advanced stage when diagnosed, so it is particularly necessary to seek markers for the early detection and diagnosis of CRC. ctDNA has been used in the diagnosis of CRC. This article reviews the progress of ctDNA in the diagnosis of CRC.
